<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158186">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02056093</url>
  </required_header>
  <id_info>
    <org_study_id>ADOREP</org_study_id>
    <nct_id>NCT02056093</nct_id>
  </id_info>
  <brief_title>Comparison of Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist</brief_title>
  <acronym>PAVANAVA</acronym>
  <official_title>Breathing Pattern Variability, Respiratory Discomfort and Work of Breathing in Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre and Marie Curie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre and Marie Curie University</source>
  <oversight_info>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In spontaneously breathing mechanically ventilated patients, the adequacy between the
      patient's demand and the level of respiratory support delivered by the ventilator is a major
      clinical issue. Neurally adjusted ventilator assist (NAVA) and proportional assist
      ventilation (PAV) have been developed to adapt the level of assistance to the patient's
      demand. These two modes have been compared to pressure support ventilation (PSV) but have
      not been compared to each other.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Breathing pattern variability</measure>
    <time_frame>February 2014</time_frame>
    <safety_issue>No</safety_issue>
    <description>The coefficient of variation (standard deviation divided by the mean) of the tidal volume (expressed in %)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-ventilator asynchrony</measure>
    <time_frame>February, 2014</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prevalence of ineffective efforts and double triggering (expressed as a number of events per minute)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Electrical diaphragm activity  Gas exchange</measure>
    <time_frame>February 2014</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured by the NAVA probe</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Intubated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intubated patients: The three modes (PSV, PAV, NAVA) will be applied in random order to each mechanically ventilated patient included in the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PSV mode</intervention_name>
    <description>Application of PSV in all patients</description>
    <arm_group_label>Intubated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PAV mode</intervention_name>
    <description>Application of PAV mode in all patients</description>
    <arm_group_label>Intubated patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NAVA</intervention_name>
    <arm_group_label>Intubated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intubated patients.

          -  Mechanical ventilation for a respiratory reason.

          -  Expected duration of Mechanical ventilation &gt; 48 hrs.

          -  Spontaneous breathing.

          -  Sedations stopped for more than 24 hours.

        Exclusion Criteria:

          -  − Main contra indications to NAVA: gastro-oesophageal surgery in the previous 12
             months, oesophageal obstruction, gastro-esophageal bleeding in the previous 30 days,
             history of esophageal varices, facial trauma or surgery, neuromuscular diseases,
             individuals with known or suspected phrenic nerve dysfunction.

               -  Main contra indications to PAV: airway leak, body weight &lt;25 kg, neuromuscular
                  diseases.

               -  Hemodynamic instability defined as the current administration of vasopressors or
                  inotropic drugs.

               -  Severe hypoxemia defined as PaO2/FiO2 ratio &lt;200.

               -  Decision to withhold life-sustaining treatment.

               -  Pregnant women.

               -  Minors &lt; 18 years.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu SCHMIDT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Association pour le Développement et l'Organisation de la Recherche en Pneumologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Pneumologie et de Reanimation médicale, Groupe hospitalier Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthieu SCHMIDT, MD</last_name>
      <email>matthieuschmidt@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Matthieu Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>December 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pierre and Marie Curie University</investigator_affiliation>
    <investigator_full_name>Matthieu SCHMIDT</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>NAVA - PAV- Breathing Variability - Asynchrony</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
